Slayback Pharma announces FDA approval of Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 mL in a multi-dose vial, the first generic equivalent of Makena(R) Injection 1,250 mg/ 5 mL multi-dose vial

PRINCETON, N.J., Jan. 2, 2019 -- (Healthcare Sales & Marketing Network) -- Slayback Pharma LLC announced today that the U.S. Food and Drug Administration ("FDA") granted approval of its abbreviated new drug application ("ANDA") for Hyd... Biopharmaceuticals, Generics, FDA Slayback Pharma, AMAG Pharmaceuticals, Makena

Source: HSMN NewsFeed - January 2, 2019 Category: Pharmaceuticals Source Type: news